Kyverna Therapeutics to Host Virtual KOL Event on Neuroimmunology CAR T Franchise

Kyverna Therapeutics will host a virtual KOL event on August 28, 2025, to discuss its neuroimmunology franchise, including its CAR T-cell therapy candidate KYV-101 for myasthenia gravis and stiff person syndrome. The event will feature KOLs from Stanford Medicine, FAU Erlangen-Nümberg, and Hannover Medical School, and will provide insights into Kyverna's strategy, treatment landscape, and near-term value-creating milestones. The event will be webcast live and available on the company's Investor Relations webpage.

Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, will host a virtual Key Opinion Leader (KOL) event on August 28, 2025, to discuss its neuroimmunology franchise. The event, scheduled from 11:00 am to 1:30 pm ET, will feature presentations by members of the company's management team and renowned KOLs from Stanford Medicine, FAU Erlangen-Nümberg, and Hannover Medical School.

The event will delve into Kyverna's neuroimmunology franchise strategy, with a focus on KYV-101, a CD19 CAR T-cell therapy candidate. Presentations will cover the treatment landscape, patient experience, and unmet need in myasthenia gravis (MG) and stiff person syndrome (SPS). The event will also provide details on KYV-101's differentiation and potential for durable drug-free, disease-free remission, as well as the specifics of its Phase 3 registrational trial in MG.

Kyverna's commercial strategy and near-term value-creating milestones will also be highlighted. The event will conclude with a Q&A session, allowing attendees to engage with management and KOLs.

The webcast will be live and can be pre-registered for at the event's registration page. The live webcast and supporting presentation materials will be available on the "Events & Presentations" section of Kyverna's Investor Relations webpage at ir.kyvernatx.com. An archived replay will also be available.

[1] https://www.marketscreener.com/news/kyverna-therapeutics-to-host-virtual-kol-event-to-highlight-neuroimmunology-car-t-franchise-ce7c5fd9d18df725